Monitoring of Serial Presurgical and Postsurgical Changes in the Serum Proteome in a Series of Patients with Calcific Aortic Stenosis
Table 2
Prescribed drugs restricted to cardiovascular disorder, blood coagulation, lipid metabolism, and calcium and phosphorus metabolism for the 19 CAS patients.
Number (%)
()
Cardiovascular disorder
ACE inhibitor
3 (15.8)
ARB
4 (21.1)
1 blocker
1 (5.3)
Antiarrhythmic drug
1 (5.3)
Ca blocker
8 (42.1)
Diuretics
6 (31.6)
Kallidinogenase (drug for Meniere disease)
1 (5.3)
Nicorandil
1 (5.3)
Nitrate (isosorbide mononitrate)
1 (5.3)
Blood coagulation
Anticoagulant (warfarin)
4 (21.1)
Antiplatelet drug
5 (26.3)
Dipyridamole
2 (10.5)
Lipid metabolism
Statin
9 (47.4)
Calcium and phosphorus metabolism
Calcification
Bisphosphonate
3 (15.8)
Cinacalcet (antihyperparathyroidism drug)
2 (10.5)
Lanthanum carbonate hydrate (drug for hyperphosphatemia)
1 (5.3)
Precipitated calcium carbonate (drug for hyperphosphatemia)
1 (5.3)
Vitamin D (alfacalcidol)
1 (5.3)
ACE inhibitor, angiotensin-converting enzyme inhibitor; 1 blocker, alpha-1 blocker; ARB, angiotensin II receptor blocker; Ca blocker, calcium channel blocker (CCB).
